Carboplatin And Paclitaxel With Or Without Viral Therapy In Treating Patients With Recurrent Or Metastatic Pancreatic Cancer

Study Overview

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

This phase II trial studies how well carboplatin and paclitaxel with or without viral therapy works in treating patients with pancreatic cancer that has come back or has spread to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Viral therapy may be able to kill tumor cells without damaging normal cells. It is not yet known whether carboplatin and paclitaxel are more effective with or without viral therapy in treating pancreatic cancer.

PRIMARY OBJECTIVES: I. To assess the improvement in progression-free survival with Reolysin (wild-type reovirus), carboplatin, and paclitaxel relative to carboplatin and paclitaxel alone in patients with recurrent or metastatic pancreatic cancer. SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of Reolysin in combination with carboplatin and paclitaxel versus without Reolysin in patients with recurrent or metastatic pancreas cancer. II. To compare the treatment groups for other efficacy endpoints such as overall response rate and overall survival. III. To define how the combination of Reolysin and carboplatin and paclitaxel (CP) modulate factors regulating immunity to reovirus and its persistence in the system circulation of patients with pancreatic cancer. IV. To prospectively establish and validate the relationship between Ras mutations in tumor samples and response to Reolysin. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I. After completion of study treatment, patients are followed up at 1 month and then every 2 months thereafter.

Pancreatic Acinar Cell Carcinoma
Pancreatic Ductal Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer

DRUG: Carboplatin
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
BIOLOGICAL: Wild-type Reovirus

NCI-2011-02567
NCI-2011-02567 (REGISTRY Identifier) (REGISTRY: CTRP (Clinical Trial Reporting Program))
OSU 10045
OSU-10045
CDR0000692060
8601 (OTHER Identifier) (OTHER: Ohio State University Comprehensive Cancer Center)
8601 (OTHER Identifier) (OTHER: CTEP)
N01CM00070 (U.S. NIH Grant/Contract)
N01CM62207 (U.S. NIH Grant/Contract)
P30CA016058 (U.S. NIH Grant/Contract)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2011-01-18	Results First Submitted 2018-01-10	Last Update Submitted that met QC Criteria 2018-02-08
First Submitted that Met QC Criteria 2011-01-18	Results First Submitted that Met QC Criteria 2018-01-10	Last Update Posted (ACTUAL) 2018-03-09
First Posted (ACTUAL) 2011-01-20	Results First Posted 2018-02-07	Last Verified 2018-02

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Arm I (wild-type reovirus, carboplatin, paclitaxel) Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.	DRUG: Carboplatin Given IV OTHER: Laboratory Biomarker Analysis Correlative studies DRUG: Paclitaxel Given IV BIOLOGICAL: Wild-type Reovirus Given IV
EXPERIMENTAL: Arm II (carboplatin, paclitaxel) Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.	DRUG: Carboplatin Given IV OTHER: Laboratory Biomarker Analysis Correlative studies DRUG: Paclitaxel Given IV

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Arm I (wild-type reovirus, carboplatin, paclitaxel)

Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

DRUG: Carboplatin

Given IV

OTHER: Laboratory Biomarker Analysis

Correlative studies

DRUG: Paclitaxel

Given IV

BIOLOGICAL: Wild-type Reovirus

Given IV

EXPERIMENTAL: Arm II (carboplatin, paclitaxel)

Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.

DRUG: Carboplatin

Given IV

OTHER: Laboratory Biomarker Analysis

Correlative studies

DRUG: Paclitaxel

Given IV

Primary Outcome Measures	Measure Description	Time Frame
Progression-free Survival Using RECIST v. 1.1	The progression-free survival distributions between the two arms will be compared using log-rank tests. Progression-free survival curves will be constructed using the Kaplan-Meier product limit method, and additional analyses will be done using the Cox proportional hazards model.	From study entry to the date of documented progression and/or death, assessed up to 4 years

Secondary Outcome Measures	Measure Description	Time Frame
Incidence of Severe (Grade 3+) Adverse Events That Are Classified as Either Possibly, Probably, or Definitely Related to Study Treatment, as Assessed by NCI CTCAE Version 4.0	Toxicities will be described for each treatment arm, but will also be compared between the arms. Fisher's exact tests will be used to quantitatively compare the incidence of severe as well as specific toxicities of interest between the treatment arms and we will graphically assess differences in maximum grades observed for toxicities between the arms.	Up to 4 years
Overall Response Rate (Partial or Complete Response) Evaluated Using the Standard RECIST v. 1.1	95% confidence intervals will be calculated. Differences in objective response rates between the treatment arms will be assessed using Fisher's exact test.	Up to 4 years
Overall Survival	Evaluated and compared between the two treatment groups using log-rank statistics and graphically using the methods of Kaplan and Meier.	From study entry to the time of death due to any cause, assessed up to 4 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Histologically confirmed adenocarcinoma of the pancreas that is recurrent or metastatic; cytological confirmation is not allowed on this study; paraffin embedded tissue from tumor blocks will be required from patients before enrolling on this study; diagnosis of pancreas cancer with histologic confirmation of adenocarcinoma would suffice
Patients must have measurable disease, defined as one lesion that can be accurately measured in at least one dimension per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (longest diameter to be recorded) as >= 10 mm by spiral computed tomography (CT) scan (CT scan slice thickness no greater than 5 mm); malignant lymph nodes will be considered measurable if they are >= 15 mm in short axis; for patients previously irradiated, the measurable lesion must be outside the radiated field
Patients must not have received any prior chemotherapy in metastatic setting; patients who have received prior chemotherapy in the adjuvant setting will not be eligible for our study; patients should not have received prior Reolysin; prior palliative radiation therapy or major surgery must have occurred at least 28 days prior to study enrollment; prior minor surgeries (such as laparoscopies) must have occurred at least 14 days prior to study enrollment; prior minor procedures such as biopsies and mediport placement must have occurred at least 48 hours prior to study enrollment
Eastern Cooperative Oncology Group (ECOG) status =< 1 (Karnofsky >= 70%)
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L International System of Units (SI) units
Platelet count >= 100 x10^9/L SI units
Hemoglobin >= 8.5 g/dL SI units
Serum creatinine =< 1.5 mg/dL OR creatinine clearance >= 60 mL/min
Bilirubin =< upper limit of normal (ULN) (=< 2 x ULN if it is non-rising for a period of 10 days prior to initiation of therapy)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X ULN
Troponin I < ULN
All patients must have signed an informed consent indicating that they are aware of the neoplastic nature of their disease and have been informed of the procedures of the protocol, the experimental nature of the therapy, alternatives, potential benefits, side effects, risks, and discomforts
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; patients must be able to avoid direct contact with pregnant or nursing women, infants and immunocompromised individuals while on study and for >= 3 weeks following the last dose of Reolysin administration
All patients must be willing and able to comply with scheduled visits, the treatment plan, and laboratory tests

Patients may not be receiving any other investigational agents or concurrent therapy with other anti-cancer agents while on study
Patients with untreated brain metastases will be excluded from this clinical trial; however, patients with resected oligometastasis are eligible if postresection magnetic resonance imaging (MRI) demonstrates resolution; gamma-knife treated patients are also eligible if there are no more than two treated metastases confined to the same area of the brain and a post treatment MRI shows a decrease in the metastases
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Reolysin or other agents used in the study
Patients may not have received any viral-based therapy within the past 6 months
Patients must have NO continuing acute toxic effects (except alopecia) of any prior radiotherapy, chemotherapy, or surgical procedures; all such effects must have resolved to Common Terminology Criteria for Adverse Events (CTCAE, version [v.] 4 ) grade =< 1 prior to study enrollment
Patients must not have grade 2 or higher baseline peripheral neuropathy according to CTCAE v. 4
Patients with uncontrolled cardiac dysfunction or arrhythmia, including a myocardial infarction in the preceding 6 months, known cardiac ejection fraction < 40%, symptomatic congestive heart failure, or unstable angina pectoris
Patients must not be receiving concurrent systemic immunosuppressive therapy
Patients must not have known human immunodeficiency virus (HIV) infection or active hepatitis B or C
Patients must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or known psychiatric illness/social situations that would limit compliance with study requirements
Patients must not have dementia or altered mental status that would prohibit informed consent
Patients must not have other known severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation, study drug administration, or may interfere with the interpretation of study results that, in the judgment of the Principal Investigator, would make the patient inappropriate for this study
Pregnant women are excluded from this study; breastfeeding should be discontinued while the mother is being treated with the agents in this clinical trial

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Anne Noonan, Ohio State University Comprehensive Cancer Center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun;24(6):1150-1158. doi: 10.1038/mt.2016.66. Epub 2016 Apr 4.
Farren MR, Mace TA, Geyer S, Mikhail S, Wu C, Ciombor K, Tahiri S, Ahn D, Noonan AM, Villalona-Calero M, Bekaii-Saab T, Lesinski GB. Systemic Immune Activity Predicts Overall Survival in Treatment-Naive Patients with Metastatic Pancreatic Cancer. Clin Cancer Res. 2016 May 15;22(10):2565-74. doi: 10.1158/1078-0432.CCR-15-1732. Epub 2015 Dec 30.

Learn

Resources

PatientS

Caregivers

Clinical Trial Record